Stock CATX PERSPECTIVE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Perspective Therapeutics, Inc.

Equities

CATX

US46489V1044

Market Closed - Nyse
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
1.58 USD -1.25% Intraday chart for Perspective Therapeutics, Inc. +5.33% +293.03%
Apr. 18 Certain Common Stock of Perspective Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 18-APR-2024. CI
Apr. 18 Certain Warrants of Perspective Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 18-APR-2024. CI

Evolution of the average Target Price on Perspective Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

4.oHMDYLk5PsX15IqXKY1Ol9psSJEJXXyOByVaN_57bPo.9yt6D_BmcbWgr8f9ZN8q45sFAOFRCk3lbU0oAcgUGK2UQjEx7m9urcagxw~0173067d71c8fa0fdaf56adefd67c254

Analyst Recommendations on Perspective Therapeutics, Inc.

B. Riley Raises Price Target on Perspective Therapeutics to $1.70 From $1.20, Maintains Buy Rating MT
Oppenheimer Adjusts Perspective Therapeutics Price Target to $1.50 From $1.20, Maintains Outperform Rating MT
B. Riley Starts Perspective Therapeutics With Buy Rating, $1.20 Price Target; Says Well-Positioned to Break Out of Biotech Pack MT
JonesTrading Initiates Perspective Therapeutics With Buy Rating, $1.40 Price Target MT
Oppenheimer Adjusts Perspective Therapeutics Price Target to $1.20 From $1, Maintains Outperform Rating MT
ISORAY : Northland Capital Starts IsoRay at Outperform with $1.25 Price Target MT
ISORAY : Oppenheimer Adjusts IsoRay PT to $1.50 From $1, Maintains Outperform Rating MT
ISORAY : Oppenheimer Starts IsoRay at Outperform with $1 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.58 USD
Average target price
1.6 USD
Spread / Average Target
+1.27%
High Price Target
1.7 USD
Spread / Highest target
+7.59%
Low Price Target
1.5 USD
Spread / Lowest Target
-5.06%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Perspective Therapeutics, Inc.

B. Riley
Oppenheimer
JonesTrading Institutional Services
Northland Securities

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. CATX Stock
  4. Consensus Perspective Therapeutics, Inc.